{{technical|date=June 2015}}

{{Drugbox
| IUPAC_name = (1-(5-fluoropentyl)-1''H''-benzo[''d'']imidazol-2-yl)(naphthalen-1-yl)methanone
| image = FUBIMINA_structure.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category =  
| legal_AU = 
| legal_CA = Schedule II
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 
| ATC_prefix =  
| ATC_suffix =  
| PubChem =  
| ChemSpiderID      = 30646758
| smiles            = O=C(C1=NC2=C(C=CC=C2)N1CCCCCF)C3=CC=CC4=CC=CC=C43
| StdInChI          = 1S/C23H21FN2O/c24-15-6-1-7-16-26-21-14-5-4-13-20(21)25-23(26)22(27)19-12-8-10-17-9-2-3-11-18(17)19/h2-5,8-14H,1,6-7,15-16H2
| StdInChIKey       = KUESSZMROAFKQJ-UHFFFAOYSA-N

<!--Chemical data-->
| C=23 | H=21 | F=1 | N=2 | O=1
| molecular_weight = 360.4 g/mol
}}

'''FUBIMINA''' (also known as '''BIM-2201''', '''BZ-2201''' and '''FTHJ''') is a synthetic [[cannabinoid]] that is the [[benzimidazole]] [[structural analog|analog]] of [[AM-2201]]<ref>{{cite web | url=https://www.caymanchem.com/app/template/Product.vm/catalog/15202 | title=FUBIMINA | publisher=Cayman Chemical | accessdate=22 June 2015}}</ref> and has been used as an active ingredient in [[synthetic cannabis]] products.<ref>{{cite journal | url=https://link.springer.com/article/10.1007/s11419-016-0312-2 | title=Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes |author1=Xingxing Diao |author2=Karl B. Scheidweiler |author3=Ariane Wohlfarth |author4=Mingshe Zhu |author5=Shaokun Pang |author6=Marilyn A. Huestis | journal=Forensic Toxicology | date=2016 | doi=10.1007/s11419-016-0312-2}}</ref> It was first identified in Japan in 2013, alongside [[MEPIRAPIM]].<ref name="Uchiyama_2014">{{cite journal | url=https://link.springer.com/article/10.1007%2Fs11419-013-0217-2 | title=Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1''H''-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products |vauthors=Uchiyama N, Shimokawa Y, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y | journal=Forensic Toxicology | year=2014 | volume=32 | issue=1 | pages=105–115 | doi=10.1007/s11419-013-0217-2}}</ref>

FUBIMINA acts as a reasonably potent [[agonist]] for the [[CB2 receptor|CB<sub>2</sub> receptor]] ([[dissociation constant|''K''<sub>i</sub>]]&nbsp;=&nbsp;23.45&nbsp;nM), with 12x selectivity over [[CB1 receptor|CB<sub>1</sub>]] (''K''<sub>i</sub>&nbsp;=&nbsp;296.1&nbsp;nM), and does not fully substitute for [[Tetrahydrocannabinol|Δ<sup>9</sup>-THC]] in rat discrimination studies.<ref>{{cite journal | url=http://jpet.aspetjournals.org/content/early/2015/06/23/jpet.115.225326.short | title=AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ<sup>9</sup>-Tetrahydrocannabinol-Like Effects in Mice |author1=Jenny L Wiley |author2=Julie A Marusich |author3=Timothy W Lefever |author4=Kateland R Antonazzo |author5=Michael T Wallgren |author6=Ricardo A Cortes |author7=Purvi R Patel |author8=Megan Grabenauer |author9=Katherine N Moore |author10=Brian F Thomas | journal=Journal of Pharmacology and Experimental Therapeutics |date=June 2015  | doi=10.1124/jpet.115.225326 | pmid=26105953 | pmc=4538877 | volume=354 | pages=328–39}}</ref>

Related benzimidazole derivatives have been reported to be highly selective [[agonist]]s for the [[Cannabinoid receptor type 2|CB<sub>2</sub> receptor]].<ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0960894X08005817 | title=Novel benzimidazole derivatives as selective CB<sub>2</sub> agonists |author1=Daniel Pagé |author2=Elise Balaux |author3=Luc Boisvert |author4=Ziping Liu |author5=Claire Milburn |author6=Maxime Tremblay |author7=Zhongyong Wei |author8=Simon Woo |author9=Xuehong Luo |author10=Yun-Xing Cheng |author11=Hua Yang |author12=Sanjay Srivastava |author13=Fei Zhou |author14=William Brown |author15=Miroslaw Tomaszewski |author16=Christopher Walpole |author17=Leila Hodzic |author18=Stéphane St-Onge |author19=Claude Godbout |author20=Dominic Salois |author21=Keymal Payza | journal=Bioorganic & Medicinal Chemistry Letters |date=July 2008  | volume=18 | issue=13 | pages=3695–3700 | doi=10.1016/j.bmcl.2008.05.073 | pmid=18522867}}</ref>

==See also==
* [[AM-694]]
* [[AM-1235]]
* [[AM-2232]]
* [[AM-2233]]
* [[BIM-018]]
* [[JWH-018]]
* [[List of AM cannabinoids]]
* [[List of JWH cannabinoids]]
* [[THJ-2201]]

==References==
{{Reflist}}

{{Cannabinoids}}

[[Category:Benzimidazoles]]
[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Organofluorides]]


{{nervous-system-drug-stub}}